Check for updates

OPEN ACCESS

EDITED BY Germano Guerra, University of Molise, Italy

REVIEWED BY Jin Zhang, University of Mississippi Medical Center, United States Chunying Li, Georgia State University, United States

*CORRESPONDENCE Lijin Zeng Zengljin@mail.sysu.edu.cn Chang Tu tuchan1725@126.com Zhen Yang yangzh8@mail.sysu.edu.cn

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 12 December 2023 ACCEPTED 03 May 2024 PUBLISHED 24 May 2024

CITATION

Zhu Y, Cai G, Lin L, Fu H, Zhang C, Zeng L, Tu C and Yang Z (2024) Age-associated declined function of endothelial progenitor cells and its correlation with plasma IL-18 or IL-23 concentrations in patients with ST-segment elevation myocardial infarction. Front. Cardiovasc. Med. 11:1351567. doi: 10.3389/fcvm.2024.1351567

COPYRIGHT

© 2024 Zhu, Cai, Lin, Fu, Zhang, Zeng, Tu and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Age-associated declined function of endothelial progenitor cells and its correlation with plasma IL-18 or IL-23 concentrations in patients with ST-segment elevation myocardial infarction

Yuanting Zhu^{1,2,3†}, Guoyi Cai^{1,3†}, Luyang Lin^{1,3†}, Hongna Fu^{1,3}, Cong Zhang⁴, Lijin Zeng^{1,3*}, Chang Tu^{5*} and Zhen Yang^{1,2,3*}

¹Division of Emergency Medicine, Department of Emergency Intensive Care Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, ²Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, ³NHC Key Laboratory of Assisted Circulation and Vascular Diseases, Sun Yat-sen University, Guangzhou, China, ⁴Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Department of Gastroenterology, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ⁵Department of Cardiology, SSL Central Hospital of Dongguan City, Dongguan, China

Background: ST-segment elevation myocardial infarction (STEMI) persists to be prevalent in the elderly with a dismal prognosis. The capacity of endothelial progenitor cells (EPCs) is reduced with aging. Nevertheless, the influence of aging on the functionality of EPCs in STEMI is not fully understood.

Method: This study enrolled 20 younger STEMI patients and 21 older STEMI patients. We assessed the Thrombolysis in Myocardial Infarction (TIMI) and Global Registry of Acute Coronary Events Risk (GRACE) scores in two groups. Then, we detected EPC migration, proliferation, adhesion, and plasma interleukin (IL)-18 and IL-23 concentrations in two groups. In addition, we analyzed the interconnection between age, EPC function, plasma IL-18 and IL-23 concentrations, and GRACE or TIMI scores in STEMI patients.

Result: GRACE and TIMI scores in older STEMI patients were higher than in younger STEMI patients, whereas EPC function declined. GRACE and TIMI scores were found to have an inverse relationship with the EPC function. In older STEMI patients, plasma concentrations of IL-18 and IL-23 increased. Plasma IL-18 and IL-23 concentrations were adversely connected to EPC capacity and positively related to GRACE and TIMI scores. Moreover, age was positively correlated with plasma IL-18 or IL-23 concentrations, as well as GRACE or TIMI scores. However, age was adversely correlated with EPC function. **Conclusion:** In patients with STEMI, aging results in declined EPC function, which may be associated with inflammatory cytokines. The current investigation may offer new perception about mechanism and therapeutic targets of aging STEMI.

KEYWORDS

endothelial progenitor cells, aging, STEMI, IL-18, IL-23, risk scores

10.3389/fcvm.2024.1351567

1 Introduction

ST-segment elevation myocardial infarction (STEMI) is a leading contributor to morbidity and death (1). STEMI in the elderly is associated with a high fatality rate, as seen by research that reported a one-year death rate of 27%, posing a severe hazard to human health (2). Currently, the global registry of acute coronary events (GRACE) risk score is employed to predict the death risk at six-months for STEMI (3), and the thrombolysis in myocardial infarction (TIMI) score can forecast the one-year mortality of STEMI (4). Reperfusion treatment is usually preferred for STEMI patients (5). Timely reperfusion treatment proportion of STEMI patients reduced with age, whereas in-hospital all-cause mortality increased (6). Therefore, exploring the underlying mechanisms of aging STEMI is of great clinical significance for its prevention and treatment.

Endothelial progenitor cells (EPCs) are involved in vascular injury repair (7). An increasing amount of research implies that aging decreases the number and functionality of EPCs, which may lead to a weakened ability to repair vascular damage (8–10). Enhanced EPC levels have been linked to a decreased risk of cardiovascular death in those with coronary artery disease (11). Nevertheless, the influence of aging on the functionality of EPCs in STEMI patients still remains unclear.

Chronic inflammation has been regarded as a primary risk factor for ageing and age-associated diseases (12). It has been reported that age was related to enhanced inflammation markers (13). Outgrowth endothelial cells (OECs) were regarded as a subtype of EPC (14). IL-8 depletion of OECs prolonged lifetime, postponed senescence, as well as augmented ability, indicating the potential association between senescence-related dysfunction and IL-8 (15). Our previous study also revealed age-associated impaired EPC function in male NSTEMI patients and the relationship between EPC function and IL-6 or IL-17 (16). These studies suggested the possible interaction between EPC function decline and interleukins in the context of aging and coronary heart disease.

Interleukin-18 (IL-18) is one of the pro-inflammatory cytokines, which has been reported to participate in cardiac inflammation and fibrosis in isoproterenol-treated mice (17, 18). IL-23 is a promoter of the cytokine IL-17, which is involved in cardiac inflammatory reactions and myocardial I/R injury (19, 20). Plasma IL-18 concentrations have been shown to be higher in healthy elderly adults than in younger adults, and plasma IL-23 concentrations were higher in centenarians than in middle-aged controls (21, 22). IL-18 can impair the function of EPCs (23). Furthermore, several studies have revealed the alteration of IL-18 and IL-23 in acute coronary syndrome (ACS) (24, 25). However, the relationship between IL-18 and IL-23 and EPC function in aging STEMI has not been studied.

Based on previous studies, we hypothesize that EPC hypofunction in aging STEMI might correlate with STEMI severity, which might be associated with plasma IL-18 and IL-23 concentrations. Therefore, we analyzed the GRACE score, TIMI score, EPC function, and plasma concentrations of IL-18 or IL-23 in younger and older patients with STEMI, as well as their

interconnection. This will provide a new insight in mechanism underlying aging STEMI patients.

2 Method

2.1 Sample collection

We collected blood samples from STEMI patients, and the diagnostic criteria for STEMI were defined by elevated levels of cardiac troponin T with compatible symptom and electrocardiogram change referred to the previous study (26). Patients aged 65 years and above were categorized as the older group, while those below 65 years were categorized as the younger group. 41 STEMI patients were included in this study, comprising 20 younger patients and 21 older patients. Venous blood was acquired to measure the plasma IL-18, IL-23 concentrations as well as the circulating EPC function.

2.2 Estimation of GRACE and TIMI scores

According to the baseline characteristics, we calculated the GRACE score on the website (www.outcomes.org/grace) (3), and the TIMI score for STEMI patients refers to a previous study (27).

2.3 Evaluation of EPC function

The migrative, adhesive and proliferative function of EPCs were evaluated referring to the previous researches (8, 28–33).

EPC migration was assessed with modified Boyden chambers. After the collection of EPCs, endothelial basal medium (0.5 ml) was used to resuspend them. 2×10^4 EPCs were added to the upper compartment of chamber, and the chamber was put into the 24-well culture plate, which included endothelial basal medium and VEGF with 50 ng/ml concentration. The EPCs were then incubated for 24 h in 37°C environment. Subsequently, the lower surface of the filter was rinsed and stabilized by 2% paraformaldehyde. The nuclei of EPCs were labeled with DAPI, and the migrated EPCs were quantified (8, 28, 29).

EPC proliferation was evaluated with 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. EPCs were digested and cultivated at serum-deprived medium on 96-well culture plates with a density of 200 μ l/well. Ten μ l of 5 mg/ml MTT was appended after 24 h, and 4-h incubation was performed. After the removal of supernatants, 10-min incubation of EPCs with 200 μ l of dimethylsulfoxide (DMSO) was performed. At 490 nm, measurements for OD were carried out (8, 28).

For evaluating the adhesion of EPCs, EPCs were gathered and mixed with basal medium containing 5% fetal bovine serum. Equal amounts of EPCs were put into dishes of culture coated by fibronectin, and 30-min incubation was performed under 37°C conditions. Then the adherent cells were quantified (30–33).

2.4 Measurement of plasma IL-18 and IL-23 concentrations

The plasma concentrations of IL-18 and IL-23 were detected using the ELISA method in accordance with the kit's guidelines (R&D Systems, Inc.).

2.5 Statistical analysis

The student *T*-test was used to identify disparities in the continuous variables of normal distribution, which were presented as mean ± SD. The Mann–Whitney *U*-test found discrepancies in the continuous variables of an abnormal distribution represented by the median (25th Percentile, 75th Percentile). Categorical variables were reported as numbers and percentages, and we applied the χ^2 test or the Fisher exact test to detect differences in categorical variables. Furthermore, the relationship between continuous variables following a normal distribution was examined using Pearson correlation analysis, while Spearman correlation analysis was utilized for continuous variables displaying an abnormal distribution. The *P*-value was generated with SPSS 21.0. *P* < 0.05 was considered to be statistically significant.

3 Results

3.1 Baseline characteristics

Table 1 outlines the baseline characteristics of younger and older STEMI patients. According to Table 1, there were significant variations in age between the younger and older groups. BMI, heart rate, systolic pressure, or diastolic pressure

 $\mathsf{TABLE}\ 1\ \mathsf{Baseline}\ \mathsf{characteristics}\ \mathsf{between}\ \mathsf{younger}\ \mathsf{and}\ \mathsf{older}\ \mathsf{STEMI}\ \mathsf{patients}.$

Baseline characteristic	Younger group (n = 20)	Older group (n = 21)
Age (year)	56.00 (45.50, 59.00)	69.00 (67.00, 73.50)*
Female, n (%)	4 (20)	5 (24)
BMI (kg/m ²)	25.00 ± 3.92	23.66 ± 2.84
Heart rate (bpm)	78.55 ± 7.79	79.19 ± 22.88
Systolic pressure (mmHg)	128.30 ± 14.02	126.48 ± 20.79
Diastolic pressure (mmHg)	78.20 ± 10.19	72.48 ± 12.11
ALT (U/L)	44.00 (28.50, 60.75)	38.00 (25.00, 69.00)
AST (U/L)	69.00 (34.50, 157.25)	100.00 (30.00, 185.00)
UREA (mmol/L)	4.65 (4.20, 7.05)	6.70 (4.60, 9.40)
Cr (umol/L)	74.50 (59.25, 88.50)	79.00 (69.00, 95.00)
LDL-C (mmol/L)	3.33 ± 0.80	3.12 ± 1.19
HDL-C (mmol/L)	1.03 ± 0. 21	1.12 ± 0.25
TC (mmol/L)	5.06 ± 1.09	4.87 ± 1.75
TG (mmol/L)	1.67 (1.16, 2.61)	1.36 (0.90, 1.71)
GLU (mmol/L)	10.65 (6.83, 16.13)	9.80 (8.40, 10.95)
GRACE score	136.00 (118.50, 160.00)	167.00 (155.00, 190.50)*
TIMI score	3.50 ± 1.70	$5.90 \pm 1.84^{*}$

BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate transaminase; Cr, creatinine; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; GLU, glucose. *P<0.05 vs. Younger group. showed no discrepancies between the younger and older groups. There were no disparities in the laboratory indicators between the two groups, including ALT, AST, UREA, Cr, LDL-C, HDL-C, TC, TG, and GLU. However, older group showed higher GRACE and TIMI scores compared to younger group.

3.2 EPC function in younger and older STEMI patients

In order to examine the impact of aging on endothelial progenitor cells in STEMI, we analyzed EPC capacity in younger and older STEMI patients. The migration of EPCs in the older group declined in contrast to the younger group (Figure 1A). The EPC proliferative function of the older group was also decreased as compared with the younger group (Figure 1B). The adhesive capacity of EPCs in the older group lessened in contrast to the younger group (Figure 1C).

3.3 The relationship between EPC function and risk scores of STEMI


To explore the association between the EPC function and STEMI risk scores, we analyzed the correlations between the EPC function and GRACE or TIMI scores. EPC migration had negative correlations with GRACE scores (Figure 2A). Similarly, the EPC proliferative capacity was negatively related to GRACE scores (Figure 2B). The adhesive capacity was also adversely associated with GRACE scores (Figure 2C). In addition, EPC migrative capacity was negatively correlated with TIMI scores (Figure 2D). The proliferation of EPCs had an inverse relationship with TIMI scores (Figure 2E). EPC adhesion was also negatively associated with TIMI scores (Figure 2F).

3.4 Plasma IL-18 and IL-23 concentrations in younger and older STEMI patients

To study the influence of aging on inflammatory responses in STEMI, an analysis of plasma IL-18 and IL-23 concentrations was conducted in younger and older STEMI patients. Figure 3A revealed that plasma IL-18 concentrations were increased in the older group in contrast to the younger group. Meanwhile, plasma IL-23 concentrations were higher in the older group than that in the younger group (Figure 3B).

3.5 The association between plasma IL-18 or IL-23 concentrations and EPC function

To explore the connection between inflammatory cytokines and EPC function, we analyzed the correlations between plasma IL-18 or IL-23 concentrations and EPC function. Plasma IL-18 concentrations exhibited a negative correlation with the migrative capacity of EPCs (Figure 4A). Plasma concentrations of IL-18







FIGURE 2


The association between EPC function and STEMI risk scores. (A–C) The relevance between EPC migration, proliferation or adhesion and GRACE scores. (D–F) The relevance between EPC migration, proliferation or adhesion and TIMI scores.




were also inversely correlated with EPC proliferation (Figure 4B). In addition, plasma IL-18 concentrations were negatively connected with the adhesive function of EPCs (Figure 4C). Similarly, plasma IL-23 concentrations had a negative correlation with EPC migration (Figure 4D). Figure 4E revealed the inverse association between plasma IL-23 concentrations and EPC proliferation. Plasma IL-23 concentrations were also negatively related to the adhesive capacity of EPCs (Figure 4F).


3.6 The correlation between plasma IL-18 or IL-23 concentrations and STEMI risk scores

To investigate the association between inflammatory cytokines and STEMI risk scores, we further analyzed the correlations





The association between plasma IL-18 or IL-23 concentrations and GRACE or TIMI scores. (A,B) The relationship between plasma IL-18 concentrations and the GRACE or TIMI scores. (C,D) The relevance between plasma IL-23 concentrations and the GRACE or TIMI scores.



between plasma IL-18 or IL-23 concentrations and STEMI risk scores. Plasma IL-18 concentrations had a positive correlation with the GRACE scores (Figure 5A). Additionally, plasma IL-18 concentrations were shown to be favorably associated with the TIMI scores (Figure 5B). Similarly, plasma IL-23 concentrations also had a positive correlation with the GRACE scores (Figure 5C). As shown in Figure 5D, plasma IL-23 concentrations were also positively related to TIMI scores.

3.7 The relationship between age and EPC function, plasma IL-18 or IL-23 concentrations, and risk scores of STEMI

As shown in Figure 6A, age exhibited a positive correlation with the GRACE scores. Similarly, age was also positively connected with TIMI scores (Figure 6B). Furthermore, age showed a negative correlation with EPC migrative capacity (Figure 6C). Analogously, age had an inverse association with proliferative function (Figure 6D). Figure 6E also indicated that age had a negative relationship with EPC adhesion. Additionally, age displayed a positive correlation with plasma IL-18 concentrations (Figure 6F). Age was also positively associated with plasma IL-23 concentrations (Figure 6G).

4 Discussion

Our study discovered that the older STEMI patients exhibited heightened GRACE and TIMI scores along with decreased EPC function compared to the younger STEMI patients. The EPC function was observed to be negatively correlated with the STEMI risk scores. Additionally, we observed that plasma concentrations of IL-18 and IL-23 were increased in the older STEMI patients. Plasma IL-18 or IL-23 concentrations showed an inverse correlation with EPC function and a positive correlation with GRACE and TIMI scores. Moreover, we found that age was adversely correlated with EPC function and positively correlated with IL-18 and IL-23 concentrations, as well as the GRACE and TIMI scores. These results revealed the impact of aging on EPC capacity of STEMI and its link to GRACE or TIMI scores and inflammation cytokines.

The GRACE risk score was used to predict the STEMI prognosis in the short and long terms (34). The TIMI score can also estimate short-term death risk and prognosis in STEMI patients (35). In our investigation, we found that the older STEMI patients had higher GRACE and TIMI scores, and age had a positive correlation with both GRACE and TIMI scores. Previous research also reported that age increased major adverse cardiovascular events (MACE) risk in acute MI patients, and age is considered an independent predictor of 30-day mortality in STEMI (36, 37). Taking these findings together, it is possible to conclude that age may be a significant factor for the prognosis of STEMI.

EPCs are essential for vascular injury repair and angiogenesis (7, 38). In response to vascular damage, bone marrow-derived EPCs reendothelize to repair vascular injury (39). Transplanting EPCs also increased neovascularization and inhibited myocardial fibrosis in ischemic myocardial rat (40). Suppressing oxidative stress delayed senescence and enhanced EPC functional capacity (41). Prior research discovered that colony formation ability, migration activity and tube-forming ability of EPCs in elderly AMI patients decreased compared to that of younger and middle-aged AMI patients (42). Similar to previous findings, our study further found attenuated migrative, proliferative and adhesive capacities of EPCs

in older STEMI patients, as well as a negative correlation between age and EPC function. These evidences revealed the influence of aging on EPC function in patients with STEMI, indicating that aging may lead to decrement in vascular repair capacity in STEMI. In addition, we found an adverse correlation between EPC function and GRACE or TIMI scores in STEMI patients. Considering prior research that highlighted GRACE and TIMI scores as prognostic indicators of STEMI (3, 4, 34), our findings imply that age-related impairment of EPC function may be linked to the risk degree and prognosis of STEMI.

Prior research has demonstrated an age-associated increase in inflammatory cytokine levels (43). In this research, we observed that plasma concentrations of IL-18 and IL-23 also increased in older STEMI patients, and age was positively linked to IL-18 and IL-23 levels, implying that age may result in augmented inflammatory responses in STEMI. In addition, IL-18 has been shown to be expressed in the atherosclerotic plaques, and IL-18 mRNA levels were higher in unstable plaques than those in stable plaques (44). IL-23 increased responses of inflammatory and reaction of oxidative stress during the myocardial I/R process (20). Our study also discovered that plasma IL-18 and IL-23 concentrations were positively correlated with the GRACE and TIMI scores in STEMI patients, suggesting that inflammation may also be correlated with the risk level and prognosis of STEMI. Furthermore, our results revealed that in STEMI patients, plasma IL-18 and IL-23 concentrations were negatively linked with EPC function, IL-18 led to impaired function of EPCs in systemic lupus erythematosus (SLE), and circulating levels of IL-18 were associated with EPC dysfunction in SLE (23). Another investigation reported that PM (polymyositis)/DM (dermatomyositis) is related to dysregulation of EPC phenotype and function that may be partly due to abnormal IL-18 and type I IFN pathways (45). Additionally, the levels of IL-23 displayed gradual increase in patients with grade I, II, and III hypertension, and were positively related to SBP and DBP (46). It was also reported that hypertensive patients had decreased function of EPCs (47). These results and our discovery imply the possible correlation between IL-23 and endothelial repair capacity in cardiovascular diseases. Taken together with the previous studies and our findings, the elevation of inflammatory cytokine may be the mechanism underlying ageassociated attenuated EPC function.

Circulating levels of IL-18 have been found to have a negative correlation with leukocyte telomere lengths (LTLs) (48), and LTL was TL proxy in other tissue (49). EPC telomere length positively correlated with their endothelial repair ability (50). Telomere attrition is known as a hallmark of aging (51), and aging can impair EPC proliferative and migrative capacity (52). Therefore, declined telomere length may be implicated in the adverse effect of IL-18 on EPC function. IL-23 was observed to elevate the expression of TNF- α under myocardial I/R injury (53). TNF- α decreased proliferative, adhesive and migrative abilities of EPCs (54). These studies imply that elevated TNF- α expression may be involved in the detrimental effect of IL-23 on EPC function. Atherosclerosis is considered to be an aging-related disease (55), and attenuated EPC proliferation and

migration were observed in atherosclerotic mice (56), which hinted the potential role of EPC dysfunction in age-related diseases and aging process. Further investigations are needed to explore the underlying mechanism.

Our investigation has some significant clinical implications. First, our findings found that in older STEMI patients, there was a decline in EPC capacity and an increase in STEMI risk scores. A negative correlation has been identified between EPC capacity and STEMI risk scores. These results indicate that the capacity of EPC may be an important indicator for evaluating the risk degree and prognosis of aging STEMI. Interventions to enhance EPC capacity may be helpful in the treatment of aging STEMI. Second, older STEMI patients had higher plasma IL-18 and IL-23 concentrations in contrast to the younger STEMI patients, and the plasma concentrations of IL-18 and IL-23 were adversely associated with EPC capacity. These findings imply that age-related decreased EPC capacity in STEMI may be attributed to enhanced levels of inflammation cytokines. IL-18 inhibitor or IL-23 inhibitor (such as guselkumab or risankizumab) (57) may be the promising potential therapeutic approach for aging STEMI. Future longitudinal clinical studies remain to be performed to verify it.

There are limitations in the investigation. First, the sample size of this study is small. Future investigation with larger sample is needed to be implemented. Second, our study is a cross-sectional study. Whether EPC dysfunction predicts the outcome of aging patients with STEMI is still undiscovered. Longitudinal researches will be launched to clarify the predictive role of EPC function in the outcome of aging STEMI.

5 Conclusion

The present study suggested there were attenuated EPC function and increased GRACE and TIMI scores in aging STEMI. The age-related EPC dysfunction in STEMI may be related to augmented inflammation cytokines levels. The current findings may provide the novel opinions into the mechanism and treatment for aging STEMI.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

YZ: Data curation, Investigation, Methodology, Writing – original draft. GC: Data curation, Formal Analysis, Writing – original draft. LL: Formal Analysis, Methodology, Writing – original draft. HF: Data curation, Validation, Writing – original draft. CZ: Data curation, Validation, Writing – original draft. LZ: Conceptualization, Investigation, Writing – review & editing. CT: Conceptualization, Funding acquisition, Writing – review & editing. ZY: Conceptualization, Funding acquisition, Writing – review & editing, Formal Analysis, Investigation.

Funding

The authors declare financial support was received for the research, authorship, and/or publication of this article.

The study was supported by the grants from the National Natural Science Foundation of China (82171578), the Science and Technology Project of Guangzhou City (2023B03J0121), Dongguan Science and Technology of Social Development Program (20221800906192), the

References

1. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: reveal: a randomized controlled trial. *JAMA*. (2011) 305(18):1863–72. doi: 10.1001/jama. 2011.592

2. Kocayigit I, Yaylaci S, Osken A, Aydin E, Sahinkus S, Can Y, et al. Comparison of effects of thrombolytic therapy and primary percutaneous coronary intervention in elderly patients with acute ST-segment elevation myocardial infarction on inhospital, six-month, and one-year mortality. *Arch Med Sci Atheroscler Dis.* (2019) 4: e82–8. doi: 10.5114/amsad.2019.85378

3. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Br Med J. (2006) 333(7578):1091. doi: 10.1136/bmj.38985.646481.55

4. Amin ST, Morrow DA, Braunwald E, Sloan S, Contant C, Murphy S, et al. Dynamic TIMI risk score for STEMI. J Am Heart Assoc. (2013) 2(1):e003269. doi: 10.1161/JAHA.112.003269

5. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. Esc guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J.* (2012) 33(20):2569–619. doi: 10. 1093/eurheartj/ehs215

6. Turk J, Fourny M, Yayehd K, Picard N, Ageron FX, Boussat B, et al. Age-related differences in reperfusion therapy and outcomes for ST-segment elevation myocardial infarction. J Am Geriatr Soc. (2018) 66(7):1325–31. doi: 10.1111/jgs.15383

7. He T, Smith LA, Harrington S, Nath KA, Caplice NM, Katusic ZS. Transplantation of circulating endothelial progenitor cells restores endothelial function of denuded rabbit carotid arteries. *Stroke.* (2004) 35(10):2378–84. doi: 10. 1161/01.STR.0000141893.33677.5d

8. Yang Z, Xia WH, Su C, Wu F, Zhang YY, Xu SY, et al. Regular exercise-induced increased number and activity of circulating endothelial progenitor cells attenuates age-related decline in arterial elasticity in healthy men. *Int J Cardiol.* (2013) 165 (2):247–54. doi: 10.1016/j.ijcard.2011.08.055

9. Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, et al. Agedependent impairment of endothelial progenitor cells is corrected by growthhormone-mediated increase of insulin-like growth-factor-1. *Circ Res.* (2007) 100 (3):434–43. doi: 10.1161/01.RES.0000257912.78915.af

10. Xia WH, Yang Z, Xu SY, Chen L, Zhang XY, Li J, et al. Age-related decline in reendothelialization capacity of human endothelial progenitor cells is restored by shear stress. *Hypertension*. (2012) 59(6):1225–31. doi: 10.1161/HYPERTENSIONAHA.111. 179820

11. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med.* (2005) 353 (10):999–1007. doi: 10.1056/NEJMoa043814

International Scientific and Technological Cooperation Project of Guangzhou Economic and Technological Development Zone (2017GH13), and the Characteristic Innovation Research Project of College Teachers (2020SWYY04).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

12. Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, et al. Molecular inflammation: underpinnings of aging and age-related diseases. *Ageing Res Rev.* (2009) 8(1):18–30. doi: 10.1016/j.arr.2008.07.002

13. Piber D, Olmstead R, Cho JH, Witarama T, Perez C, Dietz N, et al. Inflammaging: age and systemic, cellular, and nuclear inflammatory biology in older adults. *J Gerontol a Biol Sci Med Sci.* (2019) 74(11):1716–24. doi: 10.1093/gerona/glz130

14. Medina RJ, O'Neill CL, Humphreys MW, Gardiner TA, Stitt AW. Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy. *Invest Ophthalmol Vis Sci.* (2010) 51(11):5906–13. doi: 10.1167/iovs.09-4951

15. Medina RJ, O'Neill CL, O'Doherty TM, Chambers SE, Guduric-Fuchs J, Neisen J, et al. *Ex vivo* expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function. *Stem Cells.* (2013) 31 (8):1657–68. doi: 10.1002/stem.1414

16. Zeng L, Zhang C, Zhu Y, Liu Z, Liu G, Zhang B, et al. Hypofunction of circulating endothelial progenitor cells and aggravated severity in elderly male patients with non-st segment elevation myocardial infarction: its association with systemic inflammation. *Front Cardiovasc Med.* (2021) 8:687590. doi: 10.3389/fcvm. 2021.687590

17. Vecchie A, Bonaventura A, Toldo S, Dagna L, Dinarello CA, Abbate A. IL-18 and infections: is there a role for targeted therapies? *J Cell Physiol.* (2021) 236 (3):1638–57. doi: 10.1002/jcp.30008

18. Xiao H, Li H, Wang JJ, Zhang JS, Shen J, An XB, et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon beta-adrenergic insult. *Eur Heart J.* (2018) 39 (1):60–9. doi: 10.1093/eurheartj/ehx261

19. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. (2003) 278(3):1910-14. doi: 10.1074/jbc.M207577200

20. Hu X, Ma R, Lu J, Zhang K, Xu W, Jiang H, et al. IL-23 promotes myocardial I/R injury by increasing the inflammatory responses and oxidative stress reactions. *Cell Physiol Biochem.* (2016) 38(6):2163–72. doi: 10.1159/000445572

21. Niu XH, Xie YP, Yang S, Chen Y, Xu L, Zhang Y, et al. IL-18/IL-18R1 promotes circulating fibrocyte differentiation in the aging population. *Inflamm Res.* (2020) 69 (5):497–507. doi: 10.1007/s00011-020-01330-4

22. Pinti M, Gibellini L, Lo TD, De Biasi S, Nasi M, Borella R, et al. A comprehensive analysis of cytokine network in centenarians. *Int J Mol Sci.* (2023) 24(3):2719. doi: 10.3390/ijms24032719

23. Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler M, Kaplan MJ. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. *J Immunol.* (2011) 187(11):6143–56. doi: 10.4049/ jimmunol.1101284 24. Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. *Mediators Inflamm.* (2014) 2014:165742. doi: 10.1155/2014/165742

25. Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. *Clin Immunol.* (2008) 127 (1):89–97. doi: 10.1016/j.clim.2008.01.009

26. Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French registry of acute ST-elevation or non-ST-elevation myocardial infarction) 1995–2015. *Circulation.* (2017) 136(20):1908–19. doi: 10.1161/CIRCULATIONAHA.117.030798

27. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, et al. Application of the TIMI risk score for ST-elevation MI in the national registry of myocardial infarction 3. *JAMA*. (2001) 286(11):1356–59. doi: 10.1001/jama.286.11. 1356

28. Wu SH, Zhang F, Yao S, Tang L, Zeng HT, Zhu LP, et al. Shear stress triggers angiogenesis of late endothelial progenitor cells via the PTEN/Akt/GTPCH/BH4 pathway. *Stem Cells Int.* (2020) 2020:5939530. doi: 10.1155/2020/5939530

29. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res.* (2001) 89(1):E1–7. doi: 10. 1161/hh1301.093953

30. Huang PH, Chen YH, Chen YL, Wu TC, Chen JW, Lin SJ. Vascular endothelial function and circulating endothelial progenitor cells in patients with cardiac syndrome x. *Heart.* (2007) 93(9):1064–70. doi: 10.1136/hrt.2006.107763

31. Hu Z, Zhang F, Yang Z, Zhang J, Zhang D, Yang N, et al. Low-dose aspirin promotes endothelial progenitor cell migration and adhesion and prevents senescence. *Cell Biol Int.* (2008) 32(7):761–68. doi: 10.1016/j.cellbi.2008.03.004

32. Shi AW, Wang XB, Lu FX, Zhu MM, Kong XQ, Cao KJ. Ginsenoside Rg1 promotes endothelial progenitor cell migration and proliferation. *Acta Pharmacol Sin.* (2009) 30(3):299–306. doi: 10.1038/aps.2009.6

 Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. *Circulation*. (2002) 105(25):3017–24. doi: 10.1161/01.cir.0000018166.84319.55

34. Chen YH, Huang SS, Lin SJ. TIMI and grace risk scores predict both short-term and long-term outcomes in Chinese patients with acute myocardial infarction. *Acta Cardiol Sin.* (2018) 34(1):4–12. doi: 10.6515/ACS.201801_34(1).20170730B

35. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. *Circulation.* (2000) 102 (17):2031–37. doi: 10.1161/01.cir.102.17.2031

36. Wang C, Zhou L, Liang Y, Liu P, Yuan W. Interactions of ST-elevation myocardial infarction, age, and sex and the risk of major adverse cardiovascular events among Chinese adults: a secondary analysis of a single-centre prospective cohort. *Bmj Open*. (2022) 12(7):e058494. doi: 10.1136/bmjopen-2021-058494

37. Dziewierz A, Siudak Z, Rakowski T, Dubiel JS, Dudek D. Age-related differences in treatment strategies and clinical outcomes in unselected cohort of patients with ST-segment elevation myocardial infarction transferred for primary angioplasty. *J Thromb Thrombolysis.* (2012) 34(2):214–21. doi: 10.1007/s11239-012-0713-y

38. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemiaand cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med.* (1999) 5(4):434–38. doi: 10.1038/7434

39. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. *Circulation*. (2003) 108(25):3115–21. doi: 10.1161/01.CIR. 0000106906.56972.83

40. Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for

therapeutic neovascularization of myocardial ischemia. *Circulation*. (2003) 107 (3):461–68. doi: 10.1161/01.cir.0000046450.89986.50

41. Reskiawan AKR, Alwjwaj M, Ahmad OO, Rakkar K, Sprigg N, Bath PM, et al. Inhibition of oxidative stress delays senescence and augments functional capacity of endothelial progenitor cells. *Brain Res.* (2022) 1787:147925. doi: 10.1016/j.brainres. 2022.147925

42. Zhao L, Zhang S, Cui J, Huang W, Wang J, Su F, et al. TERT assists GDF11 to rejuvenate senescent VEGFR2(+)/CD133(+) cells in elderly patients with myocardial infarction. *Lab Invest.* (2019) 99(11):1661–88. doi: 10.1038/s41374-019-0290-1

43. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, et al. The origins of age-related proinflammatory state. *Blood.* (2005) 105(6):2294–99. doi: 10. 1182/blood-2004-07-2599

44. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. *Circulation*. (2001) 104(14):1598–603. doi: 10.1161/hc3901.096721

45. Ekholm I., Kahlenberg JM, Barbasso HS, Tjarnlund A, Yalavarthi S, Zhao W, et al. Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis. *Rheumatology*. (2016) 55(11):1987–92. doi: 10.1093/rheumatology/kew288

46. Ye J, Wang Y, Wang Z, Liu L, Yang Z, Wang M, et al. The expression of IL-12 family members in patients with hypertension and its association with the occurrence of carotid atherosclerosis. *Mediators Inflamm.* (2020) 2020:2369279. doi: 10.1155/2020/2369279

47. Bai YP, Xiao S, Tang YB, Tan Z, Tang H, Ren Z, et al. Shear stress-mediated upregulation of GTP cyclohydrolase/tetrahydrobiopterin pathway ameliorates hypertension-related decline in reendothelialization capacity of endothelial progenitor cells. *J Hypertens*. (2017) 35(4):784–97. doi: 10.1097/HJH.000000000001216

48. Opstad TB, Kalstad AA, Holte KB, Berg TJ, Solheim S, Arnesen H, et al. Shorter leukocyte telomere lengths in healthy relatives of patients with coronary heart disease. *Rejuvenation Res.* (2020) 23(4):324–32. doi: 10.1089/rej.2019.2258

49. Demanelis K, Jasmine F, Chen LS, Chernoff M, Tong L, Delgado D, et al. Determinants of telomere length across human tissues. *Science.* (2020) 369(6509): eaaz6876. doi: 10.1126/science.aaz6876

50. Giannotti G, Doerries C, Mocharla PS, Mueller MF, Bahlmann FH, Horvath T, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. *Hypertension.* (2010) 55 (6):1389–97. doi: 10.1161/HYPERTENSIONAHA.109.141614

51. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.* (2013) 153(6):1194–217. doi: 10.1016/j.cell.2013.05.039

52. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. *J Am Coll Cardiol.* (2005) 45 (9):1441–48. doi: 10.1016/j.jacc.2004.12.074

53. Liao Y, Hu X, Guo X, Zhang B, Xu W, Jiang H. Promoting effects of IL-23 on myocardial ischemia and reperfusion are associated with increased expression of IL-17A and upregulation of the JAK2-STAT3 signaling pathway. *Mol Med Rep.* (2017) 16(6):9309–16. doi: 10.3892/mmr.2017.7771

54. Chu H, Li H, Guan X, Yan H, Zhang X, Cui X, et al. Resveratrol protects late endothelial progenitor cells from TNF-alpha-induced inflammatory damage by upregulating kruppel-like factor-2. *Mol Med Rep.* (2018) 17(4):5708–15. doi: 10. 3892/mmr.2018.8621

55. Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. *Circ Res.* (2012) 111(2):245–59. doi: 10.1161/CIRCRESAHA.111.261388

56. Wang LY, Zhang JH, Yu J, Yang J, Deng MY, Kang HL, et al. Reduction of storeoperated Ca(2+) entry correlates with endothelial progenitor cell dysfunction in atherosclerotic mice. *Stem Cells Dev.* (2015) 24(13):1582–90. doi: 10.1089/scd.2014.0538

57. Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. *Am J Clin Dermatol.* (2021) 22(4):567–79. doi: 10.1007/s40257-021-00598-4